Gilead Sciences, Inc.

Hoffmann-La Roche Inc.

Roche Palo Alto LLC

F. Hoffmann-La Roche Ag

Elbert Chin

Zheng-Yu Yang

Jeromy J Cottell

James G Taylor

Elizabeth M Bacon

Chienhung Chou

Nathan E Wright

Gediminas J Brizgys

Sheila M Zipfel

Stephen E Ammann

John O Link

Nathan D Shapiro

Darryl Kato

Teresa Alejandra Trejo Martin

Ashley Anne Katana

Rhiannon Thomas-Tran

Scott D Schroeder

Jim W Li

Francisco Xavier Talamas

Eric Mertz

Michael Graupe

Jean-Marc Plancher

Shawn David Erickson

Javier De Vicente Fidalgo

Ryan Craig Schoenfeld

Jing Zhang

Buelent Kocer

Eric Brian Sjogren

Jennifer R Zhang

Michael L Mitchell

Winston C Tse

Gregory Notte

Robert James Weikert

Marilyn Ndukwe

Chao-I Hung

James S Cassidy

Kavoos Kolahdouzan

Stephen Ammann

Stephen Deems Gabriel

Zhi Chen

Suzanne M Szewczyk

Marina Shatskikh

Daniel G Shore

Ezra Roberts

Megan K Armstrong

Feng Chi

Nathan Shapiro

Kenneth Albert Brameld

Adam James Schrier

Qingjie Ding

Weiya Yun

David W Lin

David Scott Carter

Steven Joseph Berthel

Nan Jiang

Alfred Sui-Ting Lui

Kristen Lynn McCaleb

Qiang Zhang

Prasenjit Kumar Mukherjee

Yifan Deng

Joseph Anthony Bilotta

Laurent P Debien

Beihan Wang

Shaina V Nguyen

Joshua D Farr

Daniel Roa

Pancham Lal Gupta

Katie A Spence

Benjamin J June

David Shawn Erickson

Robert J Weikert

Han Ma

Klaus Klumpp

Jim Li

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

GLP-1R modulating compounds

Provided herein are compounds and methods for the treatment or prevention of Zika virus infection. For example, a compound of the formula(I): Wherein the variable substituents are described herein.

Tetracyclic compounds and methods for the treatment of Zika virus infection

The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

HIV inhibitor compounds

The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.

PRMT5 inhibitors and uses thereof

A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.

Pyrrolo[1,2-b]pyridazine derivatives

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.

The invention provides a compound of Formula I:

A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.

Thiadiazole IRAK4 inhibitors

Provided herein are compounds of Formula (I):

Pentacyclic derivatives as Zika virus inhibitors

Pyrrolo[1,2-b] pyridazine derivatives

Growing community of inventors

San Mateo, CA, United States of America

Elbert Chin